Plain-English translation of NCT05183126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether the timing of a infusion should be adjusted based on how much skeletal muscle (muscle tissue in your body) you have. is already an FDA-approved, commonly used cancer medication. The study is investigating whether giving this medication more slowly—over 2 to 3 hours instead of the usual 1 hour—for patients with lower muscle mass may help reduce side effects while keeping the treatment effective.
Cancer patients have varying amounts of muscle mass, which may affect how their bodies process and tolerate chemotherapy. This medication may work better and cause fewer side effects if the infusion speed is tailored to each patient's individual muscle mass rather than using a one-size-fits-all approach.
You likely qualify if…
You likely don't qualify if…
If you qualify, your muscle mass will be measured using your recent scan, and you'll receive one dose of the medication at a slower infusion speed (2 to 3 hours instead of 1 hour) if you have lower muscle mass. All other doses in your treatment plan will follow the standard 1-hour infusion schedule. The study will monitor how your body responds to the medication and collect information about how well you tolerate the treatment.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States